Decitabine/Tetrahydrouridine Drug Due Diligence Report 2026

This Decitabine/Tetrahydrouridine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

525

Registered trials

396

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Decitabine/Tetrahydrouridine can convert its Small molecule drug profile and CDA x DNMT1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Decitabine/Tetrahydrouridine (query alias: Decitabine/Tetrahydrouridine)
Modality / target	Small molecule drug; CDA x DNMT1; CDA inhibitors, DNMT1 inhibitors, Epigenetic drug
Highest global status	Phase 2
Originator	Epicdestiny
Active developers	Novo Nordisk A/S

The MCP disease footprint includes Anemia, Sickle Cell. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07773909	Phase 4	Completed	24	Primary endpoint not disclosed in English source
NCT07762508	Not Applicable	Not yet recruiting	42	Primary endpoint not disclosed in English source
NCT07706959	Phase 1/2	Not yet recruiting	108	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Pilot/Safety Study of sEphB4-HSA in Combination With a Hypomethylating Agent (HMA) for Patients With Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated With a Hypomethylating Agent

Phase 2; n=7; evaluation: Not stated in English source. Reported fields: Neutropenia CTCAE Grade ≥3 = 2 Pts

Treatment outcomes and unmet needs in patients with acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy (IC): A systematic literature review (SLR).

Not Applicable; n=55; evaluation: Positive. Reported fields: TRAE(grade 5) = 10.0 % ; CR = 25.0 % ( 17 - 35)

Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory FLT3-mutated AML.

Phase 1/2; n=88; evaluation: Positive. Reported fields: RP2D = QUIZ 26.5mg/day ; RP2D = QUIZ 26.5mg/day

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Decitabine/Tetrahydrouridine addresses Anemia, Sickle Cell. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 5 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-02-13	SK plasma to sell Janssen’s anti-cancer treatment Dacogen in Korea	Approved	Financial terms not disclosed
2014-03-31	Otsuka Acquires Rights to Eisai Cancer Treatment	Approved	Financial terms not disclosed
2014-03-31	Eisai sublicensed worldwide rights (except for the U.S., Canada, Japan, and Mexico) of Dacogen to Janssen Pharmaceutical.	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Hydrogenated pyrimidine nucleosides and nucleotides”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO